Conclusion: In summary, our in silico findings have illuminated the potential of our meticulously designed molecules as groundbreaking agents in the fight against Alzheimer’s disease, capable of simultaneously inhibiting both GSK-3β and BuChE. The gene discussed is GSK3B; the disease is early-onset autosomal dominant Alzheimer disease.